The mission of the Department of Cancer Biology is to build bridges and teams to drive the best ideas in basic and translational cancer biology and developmental therapeutics to achieve breakthrough advances in the prevention, treatment and cure of cancer. The department faculty are international leaders in brain, colorectal and prostate cancers, leukemia and myeloma, as well as cancer stem cells, mechanisms of DNA damage and repair, and fundamental molecular and cellular processes that impact microbial infections and cancer. Identifying the molecular mechanisms involved in the development and progression of human cancers as well as in normal cellular regulatory processes is our goal, enabling us to achieve our long-term objective of rapidly translating research into strategies that improve patient outcomes.

Department News

 

Flipping the Switch on Prostate Cancer Immunotherapy
05/18/2022

Dr. Nima Sharifi and a team of researchers uncovered how tumors circumvent prostate cancer therapy and identified a potential window of time after treatment when tumors may be responsive to immunotherapy.

Read More

 

First Research Published Using Cleveland Clinic’s COVID-19 Study Samples Provides Glimpse into Potential New Treatments
04/07/2022

Dr. Jung and his team of researchers published the novel COVID-19 study, which details the critical role viral gene ORF8 plays in infection and outcomes rates, using samples from Cleveland Clinic’s BioRepository.

Read More

 

NIH Funds Collaborative Study into Mechanisms of Glioblastoma Treatment Resistance
12/14/2021

Drs. Yu and Zhao will study the role of a long non-coding RNA called Lucat1 in glioma stem cells in the search for new therapeutics to help treat glioblastoma and overcome treatment resistance.

Read More

More News